CML Advocates Network

The Glivec patent expires in most countries latest on 21 Dec 2016.

The CML Advocates Network has been following the situation of TKI generics closely for 3 years, and has now provided a webinar which summarizes the current status.

This webinar answers some important questions, such as:

• What are generics, and do they differentiate from innovator products?
• Which generics of CML Tyrosine Kinase Inhibitors exist?
• What do we know about efficacy and safety?
• What information on CML generics is available to patients?
• What has the patient advocacy community done so far?
• What can patients and patient advocacy groups do about CML generics?

More can be found on our CML Advocates Network Knowledge Base on CML Generics at http://www.cmladvocates.net/generics.

If you want access to the slides, please contact Jan Geissler at .

Webstream via AuthorStream (allows to skip slides)